WHAT IS ÇLAIMED IS:

- 1. A humanized anti-VEGF antibody which binds human VEGF with a K_d value of no more than about $1 \times 10^{-8} M$.
- 2. A humanized anti-VEGF antibody which binds human VEGF with a K_d value of no more than about 5 x 10 9 M.
- 3. A humanized anti-VEGF antibody which has an ED50 value of no more than about 5nM for inhibiting VEGF-induced proliferation of endothelial cells *in vitro*.
- 4. A humanized anti-VEGF antibody which inhibits VEGF-induced angiogenesis in vivo.
- 5. The humanized anti-VEGF antibody of claim 4 wherein 5mg/kg of the antibody inhibits at least about 50% of tunor growth in an A673 in vivo tumor model.
- The humanized anti-VEGF antibody of claim 1 having a heavy chain variable domain comprising the following hypervariable region amino acid sequences: CDRH1 (GYX_1FTX_2YGMN , wherein X_1 is T or D and X_2 is N or H; SEQ ID NO:128), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 ($YPX_1YYGX_2SHWYFDV$, wherein X_1 is Y or H and X_2 is S or T; SEQ ID NO:129).
- 7. The humanized anti-VEGF antibody of claim 6 comprising the amino acid sequence of SEQ ID NO:7.
- 8. The humanized anti-VEGF antibody of claim 6 having a heavy chain variable domain comprising the following hypervariable region amino acid sequences: CDRH1 (GYTFTNYGMN; SEQ ID NO:1), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPHYYGSSHWYFDV; SEQ ID NO:3).

- 9. The humanized anti-VEGF antibody of claim 1 having a light chain variable domain comprising the following hypervariable region amino acid sequences: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS; SEQ ID NO:5) and CDRL3 (QQYSTVPWT; SEQ ID NO:6).
- 10. The humanized anti-VEGF antibody of claim 9 comprising the amino acid sequence of SEQ ID NO:8.
- 11. The humanized anti-VEGF antibody of claim 1 having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8.
- 12. An anti-VEGF antibody light chain variable domain comprising the amino acid sequence: DIQX,TQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ KPGKAPKVLIYFTSSLHSGVPSRFS GSGSGTDFTLTISSLQPEDFATXYCQQYSTVPWTFGQGTKVEIKR (SEQ ID NO:124), wherein X, is M or L.
- 13. An anti-VEGF antibody heavy chain variable domain comprising the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGYX 1FTX2YGMNWVRQAPGKGLEWVGWINTYTGEPT YAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPX 3YYGX4SHWYFDVWGQGTLV TVSS (SEQ ID NO:125), wherein X1 is T or D; X2 is N or H; X3 is Y or H and X4 is S or T.
- 14. A variant of a parent anti-VEGF antibody, wherein said variant binds human VEGF and comprises an amino acid substitution in a hypervariable region of a heavy chain variable domain of said parent antibody.
- 15. The variant of claim 14 wherein said parent antibody is a human or humanized antibody.
- 16. The variant of claim 14 which binds human VEGF with a K_d value of no more than about $1 \times 10^{-8} M$.

- 17. The variant of claim 14 which binds human VEGF with a K_d value of no more than about 5 x 10⁻⁹M.

 The variant of claim 14 which binds human VEGF with a K_d value of no more than about 5 x 10⁻⁹M.
- 18. The variant of claim 14 wherein the substitution is in CDRH1 of the heavy chain variable domain.
- 19. The variant of claim 14 wherein the substitution is in CDRH3 of the heavy chain variable domain.
- 20. The variant of claim 14 which has amino acid substitutions in both CDRH1 and CDRH3.
- 21. The variant of claim 14 which binds human VEGF with a K_d value less than that of said parent antibody.
- 22. The variant of claim 14 which has an ED50 value for inhibiting VEGF-induced proliferation of endothelial cells in vitro which is at least about 10 fold lower than that of said parent antibody.
- 23. The variant of claim 18 wherein the CDRH1 comprises the amino acid sequence: GYDFTHYGMN (SEQ ID NO:126)
- 24. The variant of claim 19 wherein the CDRH3 comprises the amino acid sequence: YPYYYGTSHWYFDV (SEQ ID NO 127).
- 25. The variant of claim 14 wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:116.
- 26. The variant of claim 25 further comprising the light chain variable domain amino acid sequence of SEQ ID NO:124.

- 27. The variant of claim 26 comprising the light chain variable domain amino acid sequence of SEQ ID NO:115.
- 28. The humanized anti-VEGF antibody of claim 1 which is a full length antibody.
- 29. The humanized anti-VEGF antibody of claim 28 which is a human IgG.
- 30. The humanized anti-VEGF antibody of claim 1 which is an antibody fragment.
- 31. The antibody fragment of claim 30 which is a Fab.
- 32. A composition comprising the humanized anti-VEGF antibody of claim 1 and a pharmaceutically acceptable carrier
- 33. A composition comprising the variant anti-VEGF antibody of claim 14 and a pharmaceutically acceptable carrier.
- 34. Isolated nucleic acid encoding the antibody of claim 1.
- 35. A vector comprising the nucleic acid of claim 34.
- 36. A host cell comprising the vector of claim 35.
- 37. A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.
- 38. The process of claim 37 further complising recovering the humanized anti-VEGF antibody from the host cell culture.

- 39. A method for inhibiting VEGF-induced angiogenesis in a mammal comprising administering a therapeutically effective amount of the humanized anti-VEGF antibody of claim 1 to the mammal.
- 40. The method of faim 39 wherein the mammal is a human.
- 41. The method of claim 39 wherein the mammal has a tumor.
- 42. The method of claim 39 wherein the mammal has a retinal disorder.